Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial

Hepatology

Volumn 56, Issue 6, 2012, Pages 2106-2115

  De Meyer, Sandra ^a   Dierynck, Inge ^a   Ghys, Anne ^a   Beumont, Maria ^a   Daems, Bjorn ^a   Van Baelen, Ben ^a   Sullivan, James C ^b   Bartels, Douglas J ^b   Kieffer, Tara L ^b   Zeuzem, Stefan ^c   Picchio, Gaston ^d  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b VERTEX PHARMACEUTICALS   (United States)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IC 50; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INHIBITORY CONCENTRATION 50; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TREATMENT FAILURE;

EID: 84870018199     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25962     Document Type: Article

References (29)

1. Lin K, Perni RB, Kwong AD, Lin C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 2006; 50: 1813-1822.
2. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024 (Erratum: N Engl J Med 2011;365:1551).
3. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
4. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
5. ® (telaprevir) tablets. Summary of Product Characteristics October 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002313/WC500115529.pdf [Accessed 19 October 2011].
6. ® (telaprevir) tablets. FDA Prescribing Information May 2011. Available from http://pi.vrtx.com/files/uspi_telaprevir.pdf [Accessed 19 October 2011].
7. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618-1628. e2.
8. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandao-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150: 528-540.
9. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
10. Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Disease 2003; 7: 45-66.
11. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65: 202-212.
12. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-462.
13. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777.
14. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. HEPATOLOGY 2009; 50: 1709-1718.
15. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. HEPATOLOGY 2007; 46: 631-639.
16. Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang E, Tigges A, et al. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One 2012; 7: e34372.
17. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics 2005; 21: 379-384.
18. Liddell FD. Simplified exact analysis of case-referent studies: matched pairs; dichotomous exposure. J Epidemiol Community Health 1983; 37: 82-84.
19. Kieffer TL, Bartels DJ, Sullivan JC, Bartels D, Sullivan JC, Adiwijaya BS, et al. Clinical virology results from telaprevir phase 3 study ADVANCE. HEPATOLOGY 2010; 52: 879A.
20. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198: 800-807.
21. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. HEPATOLOGY 2008; 48: 1769-1778.
22. Chevaliez S, Rodriguez C, Soulier A, Ahmed-Belkacem A, Hézode C, Pawlotsky JM. Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations. J Hepatol 2011; 54(Suppl 1): S30.
23. Howe JA, Qiu P, Ogert RA, Mendez P, Brass C, Albrecht J, et al. Frequencies of resistance-associated amino acid variants detected by 454-sequencing during combination treatment with boceprevir plus pegintron (peginterferon alfa-2b)/ribavirin in HCV (GT1)-infected patients. J Hepatol 2011; 54(Suppl 1): S176.
24. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
25. Brass C, Barnard RJO, Howe JA, Ogert RA, Ralston R, Boparai N, et al. Sustained virologic response and boceprevir resistance-associated variants observed in patients infected with HCV genotype 1a/1b when treated with boceprevir plus peginterferon alfa-2b/ribavirin:. J Hepatol 2011; 54(Suppl 1): S471.
26. Zhou Y, Müh U, Hanzelka BL, Bartels DJ, Wei Y, Rao BG, et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 2007; 282: 22619-22628.
27. Vierling JM, Ralston R, Lawitz EJ, McCone J, Gordon S, Pound D, et al. Long-term outcomes following combination treatment with boceprevir plus peg-intron/ribavirin (P/R) in patients with chronic hepatitis c, genotype 1 (Chc-G1). J Hepatol 2010; 52(Suppl 1): S470-S471.
28. Codoner FM, Pou C, Thielen A, Garcia F, Delgado R, Dalmau D, et al. Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. PLoS One 2011; 6: e19461.
29. Zeuzem S, Sulkowski M, Zoulim F, Sherman KE, Alberti A, Wei L-J, et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study. [Abstract] HEPATOLOGY 2010; 52(Suppl): 436A.